CIAPM Request for Proposals 2018 - Selection Committee

Overview by Expertise

Selection Committee Member Institution Expertise
Shawneequa Callier The George Washington University Health Disparities / Ethics
Rachel Ceballos Fred Hutchinson Cancer Research Center Health Disparities / Behavioral Health
Yvonne Yu-Feng Chan Mount Sinai Health System Digital Health
Elizabeth Cohn City University of New York Ethics / Health Disparities
Meg Gaines University of Wisconsin Health Advocacy / Care Co-creation
Ernest Hawk MD Anderson Cancer Center Cancer Prevention & Control / Disparities
Elaine Mardis – CHAIR Ohio State University Cancer / Genomics / Immunogenomics
Mark Rubin Weill Cornell Medicine Genomics / Precision Oncology
Stanley Shaw Harvard University Functional Genomics / Digital Health
Sharon Terry Genetic Alliance Participant Advocacy & Engagement
Pingkun Yan Rensselaer Polytechnic Institute Medical Image Analysis

Listed in alphabetical order 

Shawneequa Callier, JD, MA 

Associate Professor, Clinical Research and Leadership
School of Medicine and Health Sciences
The George Washington University

Shawneequa Callier, J.D., M.A., is an Associate Professor in the Department of Clinical Research and Leadership and Director of Doctoral Research in the Translational Health Sciences Ph.D. program at the George Washington University School of Medicine and Health Sciences (SMHS). Professor Callier teaches courses in bioethics and health care law in a variety of programs at SMHS. She is also a Professorial Lecturer in Law at the George Washington University Law School and Special Volunteer at the Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health. Her research focuses on topics related to precision medicine research and health disparities, diversity and inclusion in genomic research, genomic incidental findings, the use of race in medicine, pharmacogenomics, and the use of personalized genomic testing as an educational tool. 

Prior to joining the GWU faculty, Professor Callier completed a post-doctoral fellowship at the Center for Genetic Research Ethics and Law, an interdisciplinary center for excellence funded by the National Human Genome Research Institute and located in the Bioethics Department of Case Western Reserve University’s School of Medicine. Earlier in her career, Professor Callier practiced health care law as an attorney in Washington, D.C. She also interned at the World Health Organization and the Nuffield Council on Bioethics where she examined international healthcare ethics policies and human genetics laws and guidelines. Back to top ↑

Rachel Ceballos, PhD

Assistant Member, Public Health Sciences Division
Fred Hutchinson Cancer Research Center 
Affiliate Assistant Professor, School of Public Health
University of Washington

Dr. Ceballos is currently an Assistant Member in the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center and Affiliate Assistant Professor in the School of Public Health at the University of Washington in Seattle, WA. Her research involves development and evaluation of culturally-appropriate interventions to improve emotional well-being and health education opportunities for Latino and African-American cancer survivors.  Her work also focuses on understanding underserved Latinos’ interests, beliefs, and preferences for biomedical research participation. The centerpiece of Dr. Ceballos’s research is the use of community based participatory research (CBPR) practices. CBPR involves reciprocal learning and active community collaboration at all levels of the research process. Trained as an interdisciplinary scientist, with both laboratory and community-level research experience, Dr. Ceballos uses patient reported psychosocial assessment and biological outcome measures to evaluate intervention effectiveness.  She has received recognition for partnerships with community organizations and received the 2016 Aetna Award for Excellence in Research on Older Women and Public Health. Dr. Ceballos is a Steering Committee Member for the National Latino Cancer Summit and an Advisory Board member for the Susan G. Komen Puget Sound LGBTQ Initiative. Back to top ↑

Yvonne Yu-Feng Chan, MD, PhD, FACEP

Director, Center for Digital Health 
Associate Professor, Genetics and Genomic Sciences 
Associate Professor, Emergency Medicine
Icahn Institute for Genomics and Multiscale Biology 
Icahn School of Medicine at Mount Sinai

Yvonne Yu-Feng Chan, MD, PhD, FACEP is the director of the Center for Digital Health at the Icahn School of Medicine at Mount Sinai.  She is a leader in mobile health and digital health research, and a board-certified Emergency physician. The mission of her Digital Health Center is to rapidly drive large-scale participation of patients and consumers in biomedical research, by leveraging the latest mobile/digital technology and advanced analytic techniques to uncover novel insights and actionable results to advance healthcare.

Dr. Chan was the principal investigator for the Mount Sinai Asthma Mobile Health Study using the Asthma Health app powered by Apple’s ResearchKit framework. This pioneering virtual study of >10,000 participants from 3 countries demonstrated that a broad scale clinical study could be conducted in its entirety via a smartphone application, including remote participant recruitment, consent, prospective collection of data including geolocation, environmental and device data, as well as secure bi-directional data exchange between participants and investigators. Recently, Dr. Chan and her digital health team created and deployed a digital platform to scale Mount Sinai’s recruitment and engagement of the institution’s DNA biobank research participants. Additionally, she is also the Mount Sinai principal investigator for the NIH U01 “Practice-Based Research to Improve Self-Management Support (PRISMS) Sensor Development Projects for Pediatric Asthma study”- an innovative smartphone and biosensor device research collaboration with the Center for Bioelectronics and Biosensors at Arizona State University and University of Southern California. Back to top ↑

Elizabeth Gross Cohn, RN, PhD

Rudin Professor
City University of New York–Hunter College
Adjunct Senior Research Scientist
Columbia University

Elizabeth Gross Cohn, RN, NP, PhD, FAAN was named a 2016 White House Champion of Change in Precision Medicine for her work at the intersection of precision medicine, public health and health equity.  She is the Rudin Professor at Hunter-Bellevue School of Nursing, City University of New York and an adjunct Senior Research Scientist at Columbia University. Her work focuses on urban community-health, engagement of underrepresented communities, community-engaged research and the ethical, legal, social and scientific issues in precision medicine and public health. She has had funding from the National Institutes of Health for the ethical, legal and social considerations of genetics and genomics, and for an interactive mobile museum exhibit—Gene Convene—that promotes genomic literacy in urban communities using popular culture.  Her work with a Native American Reservation, the Unchung Nations Initiative to End Diabetes (UNITED) was funded by the Patient-Centered Outcomes Research Institute, and a grant to strengthen resilience in communities (RESCUE) was funded by the New York State Department of Health. Her work has been featured in the New York Times, on National Public Radio’s All Things Considered, in The Atlantic and in Men’s Health. She is the author of an Elsevier cardiology text, Flip and See ECG, now in its fourth edition. She is an alum of the Robert Wood Johnson Nurse Faculty Scholars Program.

Dr. Cohn received her Associate Degree from Nassau Community College, her bachelor’s Degree from the State University of New York at Purchase, her Master’s Degree and Nurse Practitioner from the State University of New York at Stony Brook and her Doctorate from Columbia University. Back to top ↑

Martha E. “Meg” Gaines, JD, LLM

Distinguished Clinical Professor
Director, Center for Patient Partnerships
University of Wisconsin Schools of Law, Medicine, Nursing & Pharmacy

Meg Gaines founded and directs the interdisciplinary Center for Patient Partnerships at the University of Wisconsin. The Center’s mission is to disrupt dysfunctional health care by restoring people to the core of care.  The Center advocates with patients to get the care they need, while teaching future professionals to see their patients as partners; promotes changes in health care policy at the local, state and federal levels; and conducts primary, mixed methods research focused on patients’ experiences of their care. Students derive from a breadth of disciplines including medicine, nursing, law, health systems, genetic counseling, industrial engineering, and pharmacy, and work in interprofessional teams to provide advocacy services to patients with life-threatening and serious chronic illnesses.

Professor Gaines’ work focuses on consumer engagement and empowerment in health care reform where she has been privileged to collaborate with the Robert Wood Johnson Foundation, the Kaiser Family Foundation, the American Board of Internal Medicine Foundation, the Josiah Macy Jr Foundation, and the National Cancer Institute among others.  She serves on the National Cancer Research Advocates of the NCI, on the Boards of the National Quality Forum and the Academy on Communication in Healthcare, recently co-chaired the Josiah Macy Jr Foundation annual conference “Partnering with Patients, Families, and Communities to Link Interprofessional Practice and Education.” She co-authored the Charter on Organizational Professionalism for Healthcare Organizations, as a companion to the Charter on Medical Professionalism of the Choosing Wisely Campaign. Back to top ↑

Ernest Hawk, MD, MPH

Vice President and Division Head, Cancer Prevention and Population Sciences
T. Boone Pickens Distinguished Chair for Early Prevention of Cancer
The University of Texas MD Anderson Cancer Center

Ernest Hawk, MD, MPH, is vice president and division head for Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the T. Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment, as well as co-leader of MD Anderson’s Cancer Prevention and Control Platform. The Platform plans, implements, and evaluates evidence-based actions in public policy, professional/public education, and community-based service delivery to reduce cancer and related risk factors at the population level. His personal research interests include preclinical and clinical drug development for cancer prevention, prevention clinical trials, and the inclusion of diverse and underserved populations in cancer research and control programs to improve outcomes and reduce disparities. He earned his medical degree from Wayne State University and his MPH degree from Johns Hopkins University. Back to top ↑

Elaine Mardis, PhD

Nationwide Foundation Endowed Chair in Genomic Medicine
Co-Executive Director, Institute for Genomic Medicine at Nationwide Children's Hospital
Professor of Pediatrics
The Ohio State University College of Medicine

Elaine Mardis, PhD is co-Executive Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital and the Nationwide Foundation Endowed Chair of Genomic Medicine. She also is Professor of Pediatrics at The Ohio State University College of Medicine.  Dr. Mardis joined Nationwide Children’s Hospital in 2016.

Educated at the University of Oklahoma with a B.S. in Zoology and a Ph.D. in Chemistry and Biochemistry, Dr. Mardis did postgraduate work in industry at BioRad Laboratories. She was a member of the faculty of Washington University School of Medicine from 1993-2016.

Dr. Mardis has authored over 350 articles in prestigious peer-reviewed journals and has written book chapters for several medical textbooks.  She serves as an associate editor for three peer-reviewed journals (Disease Models and Mechanisms, Molecular Cancer Research, and Annals of Oncology) and is Editor-in-Chief of Molecular Case Studies, published by Cold Spring Harbor Press.  Dr. Mardis has given lectures at scientific meetings worldwide and was awarded the Morton K Schwartz award from the American Association for Clinical Chemistry in 2016.  She has been listed since 2013 as one of the most highly cited researchers in the world by Thompson Reuters.  Dr. Mardis has been a member of the American Association for Cancer Research (AACR) since 2007, was the program committee chair for the 2018 AACR Annual Meeting and is the AACR President-elect. Back to top ↑

Mark A. Rubin, M.D.

Professor of Pathology of Laboratory Medicine, Weill Cornell Medicine
Director, Department for BioMedical Research, University of Bern, Switzerland
Project Leader, Precision Medicine Inselspital, Bern University Hospital, Switzerland

Professor Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Subsequently, Rubin’s laboratory has been instrumental in establishing the mechanistic basis by which defined genomic alterations drive prostate cancers. His group discovered that mutations in the SPOP gene are among the most common in prostate cancer. Moreover, they demonstrated these mutations lead to genome instability, which permits prostate cancer cells to become more aggressive and resistant to therapy. Rubin’s work established that neuroendocrine prostate cancers arise from the aberrant activity of novel drivers, NMYC and AURKA that are distinct from other types of prostate cancers. Based on this work, Mark Rubin is involved in clinical trials aimed at evaluating the efficacy of AURKA inhibitors in treating neuroendocrine prostate cancer. He is also developing novel drugs to target advanced prostate cancer. Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. As the founding director of the Englander Precision Medicine Institute at Weill Cornell (New York, USA), he developed a cutting-edge genomics clinical lab and received the first New York State approval to use whole exome sequencing in the diagnosis and treatment of a broad variety of cancers. In May 2017, Prof. Rubin joined the University of Bern as Professor and Director of the Department for BioMedical Research and also as Project Leader for Precision Medicine at the University Hospital of Bern. Back to top ↑

Stanley Y. Shaw, MD, PhD

Associate Dean for Executive Education
Harvard Medical School
Chief Science Officer, One Brave Idea
Brigham & Women’s Hospital

Stanley Y. Shaw, MD PhD is the inaugural Associate Dean for Executive Education at Harvard Medical School. In this role, he designs and directs a growing portfolio of programs for companies and executive leaders from diverse sectors of health care, from small biotechs to Fortune 100 companies. Dr. Shaw is also the Chief Scientific Officer for One Brave Idea (at Brigham and Women’s Hospital), an initiative funded by the American Heart Association, Verily and Astra Zeneca to understand and treat the earliest changes in coronary heart disease. His research seeks to understand how digital health, bioinformatics, the gut microbiome and patient-reported data can be leveraged to better assess health and disease. Previously, he co-founded the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital, and his team led the development of one of the first ResearchKit iPhone apps in partnership with Apple. Dr. Shaw received his AB in Chemistry & Physics from Harvard College, and his MD and PhD (in Biophysics) from Harvard. He completed his clinical training in Internal Medicine and Cardiology at Massachusetts General Hospital. Back to top ↑

Sharon F. Terry

President and CEO
Genetic Alliance

Sharon F. Terry is President and CEO of Genetic Alliance, an enterprise engaging individuals, families and communities to transform health.  Genetic Alliance works to provide programs, products and tools for ordinary people to take charge of their health and to further biomedical research.

As ‘just a Mom’ with a master’s degree in theology, she cofounded PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE), in response to the diagnosis of PXE in her two children in 1994.  With her husband, she co-discovered the ABCC6 gene, patented it to ensure ethical stewardship in 2000, and assigned their rights to the foundation.  She subsequently developed a diagnostic test and conducts clinical trials.  She is the author of 150 peer-reviewed papers, of which 30 are clinical PXE studies. Her story is the topic of her TED Talk and TED Radio Hour.

In her focus at the forefront of consumer participation in genetic research, services and policy, she serves in a leadership role on many of the major international and national organizations, including the Precision Medicine Initiative Cohort Advisory Panel; Accelerating Medicines Partnership; the Cures Acceleration Network Review Board, and the Advisory Council, National Center for Accelerating Translation Science, NIH; National Academy of Medicine Roundtable on Genomics and Precision Health; the PhenX scientific advisory board; the Global Alliance for Genomics and Health; the International Rare Disease Research Consortium Executive Committee; and as Founding President of EspeRare Foundation of Geneva, Switzerland. She is Co-PI of the PCORnet Coordinating Center and Chair of the PCORnet Engagement Committee. She was a member of the Blue Ribbon Panel’s Working Group on Enhanced Data Sharing for the Cancer Moonshot. She received the Health 2.0 Health Activist award in 2016. In 2017, she co-founded the People Centered Research Foundation. Back to top ↑

Pingkun Yan, PhD

Assistant Professor, Biomedical Engineering
Rensselaer Polytechnic Institute

Dr. Pingkun Yan is currently an Assistant Professor at the Department of Biomedical Engineering at Rensselaer Polytechnic Institute (RPI). Before joining RPI, he was a Senior Scientist of Philips Research working at the clinical site at the National Institutes of Health (NIH). His research interests are in the translational medical research domain focusing on medical imaging informatics and interventional oncology guidance using machine learning techniques through close collaboration with clinicians. Dr. Yan has published over 80 peer reviewed articles in well recognized journals and international conferences. His research work has also resulted in a number of patent filings and issued patents.

Dr. Yan obtained his Ph.D. from National University of Singapore in 2006. In 2005, he received the prestigious MICCAI Best Paper Award for his work on segmenting blood vessels from magnetic resonance angiography by modeling the capillary action. In 2008, his project on image-guided prostate biopsy was one of the 4 finalists of the Innovation in Industry Award by New York Academy of Sciences, which stood out from 120 nominees across the state of New York, for its contribution to prostate cancer detection. He is currently serving as an associate editor of multiple international journals, including Machine Vision and Applications (Springer) and Neurocomputing (Elsevier). He co-organized 6 international workshops and 4 international journal special issues, and has served as a program committee member for more than 50 international conferences. He is also a regular reviewer of a large number of international journals and conferences. Back to top ↑